Financial Performance - Revenue for Q1 2025 reached $586.01 million, a 110.5% increase compared to $278.17 million in Q1 2024[22] - Gross profit for Q1 2025 was $430.69 million, up 88% from $229.10 million in Q1 2024[22] - Net income for Q1 2025 was $49.49 million, significantly higher than $11.13 million in Q1 2024, representing a 345% increase[22] - Total revenue for the three months ended March 31, 2025, was $586.0 million, a 110.7% increase from $278.2 million in the same period of 2024[51] - Adjusted EBITDA for Q1 2025 was $91.1 million, compared to $32.3 million in Q1 2024, with an Adjusted EBITDA margin of 16%[165] - Segment net income for the three months ended March 31, 2025, was $49.49 million, compared to $11.13 million in 2024[131] - Free Cash Flow for the three months ended March 31, 2025, was $50.1 million, compared to $11.9 million in 2024, representing an increase of $38.2 million[167] Assets and Liabilities - Total current assets increased to $446.96 million as of March 31, 2025, compared to $395.83 million at the end of 2024, reflecting a 12.9% growth[20] - Total assets grew to $891.71 million as of March 31, 2025, up from $707.54 million at the end of 2024, marking a 26% increase[20] - Total liabilities increased to $342.45 million as of March 31, 2025, compared to $230.82 million at the end of 2024, a rise of 48.4%[20] - Cash and cash equivalents rose to $273.74 million as of March 31, 2025, compared to $220.58 million at the end of 2024, an increase of 24%[20] - Total short-term investments decreased to $48.9 million as of March 31, 2025, down from $79.7 million at the end of 2024, primarily due to a reduction in U.S. Treasury bills[72] Revenue Streams - Online revenue reached $576.4 million for the three months ended March 31, 2025, compared to $267.8 million in the prior year, representing a 115.0% growth[51] - The Company’s wholesale revenue for the three months ended March 31, 2025, was $9.6 million, slightly down from $10.4 million in the same period of 2024[51] - Monthly Online Revenue per Average Subscriber rose to $84, a 53% increase from $55 in the prior year[148] - Online Revenue for Q1 2025 reached $576.4 million, a 115% increase from $267.8 million in Q1 2024, driven by new Subscriber growth and GLP-1 offerings generating approximately $230 million[149] Expenses - Operating expenses for Q1 2025 totaled $372.79 million, up from $219.19 million in Q1 2024, reflecting a 69.9% increase[22] - Marketing expenses rose to $231.2 million for the three months ended March 31, 2025, an increase of $100.7 million or 77% from $130.6 million in 2024[184] - Customer acquisition costs increased to $201.6 million in the three months ended March 31, 2025, compared to $113.2 million in 2024, reflecting a rise of $88.4 million[184] - Technology and development expenses rose by $14.6 million or 95% to $29.9 million for the three months ended March 31, 2025, compared to $15.3 million for the same period in 2024[186] Acquisitions and Investments - The Company acquired manufacturing assets from C S Bio Co. for up to approximately $39.1 million, including $32.7 million upfront and a potential earn-out of $32.7 million based on performance conditions[63] - The acquisition of Sigmund NJ, LLC (Trybe Labs) was completed for total cash consideration of $5.1 million, with $5.0 million recorded as goodwill due to the expected future economic benefits[65][66] - The Company acquired MedisourceRx for $31.0 million, with acquisition costs of $1.4 million recorded as general and administrative expenses[67][68] Stock and Shareholder Information - The 2023 Share Repurchase Program authorized the repurchase of up to $50.0 million of Class A common stock, which was fully utilized by December 31, 2024, while the 2024 program allows for an additional $100.0 million in repurchases[100][101] - During the three months ended March 31, 2025, the Company released 1,938,929 gross shares of Class A common stock upon vesting of RSUs, compared to 1,424,493 shares in the same period of 2024[102] - As of March 31, 2025, there were 65,402,137 shares of Class A common stock reserved and 22,510,375 shares available for grant under the 2020 Stock Plan[104] Regulatory and Market Environment - The Company operates in a highly regulated environment, and failure to comply with laws and regulations could lead to substantial penalties and operational restructuring[218] - The company faces competition from large, established healthcare providers and technology companies, which may hinder its competitive effectiveness[217] - The company anticipates that the resolution of the semaglutide shortage may lead to a decrease in Subscriber retention metrics in the near term[157] Future Outlook - The company plans to continue investing in fulfillment, distribution, and operating capabilities, including its recently acquired lab testing and peptide manufacturing facilities[158] - The company expects to expand into new health and wellness specialties, requiring financial investments in marketing and operational capabilities[160] - The company has experienced rapid growth in recent fiscal years and plans to continue investing in growth, although future growth levels may not match past performance[217]

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Af irms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EB ...

Core Viewpoint - Hims & Hers Health, Inc. is expected to report strong revenue and earnings growth for the first quarter of 2025, driven by increased subscriber numbers and expanded product offerings [4][5][15]. Group 1: Performance Metrics - The company ended Q4 2024 with nearly 2.2 million subscribers, a 45% year-over-year increase [2]. - Monthly online revenue per average subscriber rose by 37.7% year-over-year in Q4 2024, attributed to the scaling of GLP-1s and a shift to premium offerings [2]. - Hims & Hers generated 2.8 million net orders in Q4 2024, marking a 22.1% year-over-year increase [2]. - Average order value increased by 63.1% year-over-year in Q4 2024 [2]. Group 2: Revenue and Earnings Estimates - The Zacks Consensus Estimate for Q1 2025 revenues is $538.1 million, reflecting a 93.4% increase from the prior year [4]. - The consensus estimate for EPS is 12 cents, indicating a 140% surge from the previous year's figure [4]. Group 3: Strategic Developments - The company has expanded its brand to include a wider range of health specialties, which is expected to enhance revenue potential [3]. - A long-term collaboration with Novo Nordisk aims to improve accessibility to obesity treatments, potentially boosting revenues [15]. - Recent acquisitions, including a peptide facility and an at-home lab testing facility, are expected to strengthen the company's supply chain and service offerings [16]. Group 4: Valuation and Market Position - Hims & Hers has a forward 12-month price-to-sales (P/S) ratio of 3.2X, which is below the industry average of 5.3X [10]. - The company is trading at a discount compared to peers like Veeva Systems and Inspire Medical, suggesting potential for growth [11]. Group 5: Stock Performance - Over the past three months, Hims & Hers shares have decreased by 7.1%, outperforming the declines of its sector and the S&P 500 [7]. - Compared to peers, Hims & Hers has shown relative resilience, with some competitors experiencing larger declines [9].

Hims & Hers (NYSE: HIMS ) is changing the way healthcare is administered in the 21st century, which is increasingly reflected by its surging topline. The company grew its 2024 revenue by 69% YoY to $1.5"AWS Certified AI Practitioner Early Adopter"I am a DevOps Engineer for a major, wholly owned subsidiary of a large-cap Fortune 500. I am a true subject-matter expert on the actual buildout, deployment, and maintenance of AI tools and applications. I have increasingly deep knowledge on the science behind gene ...

Core Insights - Hims & Hers Health (HIMS) and Novo Nordisk (NVO) have announced a partnership to enhance obesity care through telehealth, allowing access to Novo Nordisk's FDA-approved weight loss drug Wegovy on Hims & Hers' platform [1][7][15] Company Performance - Hims & Hers stock has surged over 30% in 2025 following the partnership announcement, while Novo Nordisk's stock has declined more than 20% year to date [2] - Hims & Hers has experienced a remarkable stock performance, with shares soaring over 600% in the last three years, compared to Novo Nordisk's 15% increase [3] Sales and Earnings Projections - Hims & Hers total sales are projected to increase by 58% in fiscal 2025 to $2.33 billion, with further growth of 21% expected in FY26 to $2.84 billion [4] - Annual earnings for Hims & Hers are anticipated to rise over 160% this year to $0.72 per share, with FY26 EPS forecasted to increase by 48% to $1.07 [5] EPS Estimates - Hims & Hers has seen positive earnings estimate revisions, with FY25 and FY26 EPS estimates increasing by 14% and 12% respectively in the last 30 days [11] - Novo Nordisk's FY25 EPS estimates have slightly decreased over the last quarter but increased by 1% in the last month, while FY26 estimates have risen by 2% [13] Market Outlook - Novo Nordisk's sales are expected to grow by 18% in FY25 and another 15% in FY26, reaching $57.1 billion, with EPS growth projected at 17% this year and 22% in FY26 to $4.71 per share [8]

Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and Teladoc Health, Inc. (TDOC) emerging as key players [1][2] Group 1: Hims & Hers Health, Inc. (HIMS) - HIMS is expanding into new specialty areas that can be treated effectively via telehealth, including weight loss, sleep disorders, and hypertension, which are prevalent among its customer base [3] - The company has announced a collaboration with Novo Nordisk to enhance accessibility and affordability of obesity care [4] - Over 65% of new subscribers in 2024 benefited from personalized products, supported by the MedMatch AI tool for customized treatment plans [5] - HIMS has shown strong stock performance, rallying 158.5% over the past year, compared to TDOC's decline of 44.3% [9] Group 2: Teladoc Health, Inc. (TDOC) - TDOC is broadening its virtual care offerings across the healthcare continuum, including primary care, chronic care, and mental health management [6] - The company has established a global distribution network, facilitating partnerships with insurers and expanding its services internationally [7] - TDOC aims to enhance its capabilities through selective acquisitions, such as the agreement to acquire Catapult Health [8] - Despite its growth, TDOC's stock has underperformed, with a decline of 29.7% over the past three months [9] Group 3: Stock Performance & Valuation - HIMS is trading at a forward price-to-sales (P/S) ratio of 3.1X, above its three-year median of 2.2X, while TDOC's forward sales multiple is at 0.5X, below its median of 1.2X [10] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 166.7% improvement from 2024, while TDOC's estimate implies an 85% improvement in loss per share [12][15] - Analysts' average price target for HIMS is $27.50, indicating a potential decline of 53.5%, while TDOC's average target is $10.90, implying a decline of 19.3% [16][18] Group 4: Investment Outlook - HIMS is viewed as a more stable investment opportunity with strong profitability and user engagement, earning a Zacks Rank 2 (Buy) [21] - TDOC, with a Zacks Rank 3 (Hold), is expanding but faces challenges in its business environment, making HIMS a more compelling choice for investors seeking lower execution risk [22]

Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today’s best pick seems to be in the medical sector. It shows investors a major fundamental strength that has been noticed by other major players in the industry, pushing future upside potential higher. Hims & Hers Health TodayHIMSHims & Hers Health$32.11 -2.93 (-8.35%) 52-Week Range$11.20▼$72.98P/E Ratio72.99Price Target$36.92Add to W ...

Company Overview - Hims & Hers Health, Inc. (HIMS) shares increased by 23% to close at $35.04, with trading volume significantly higher than usual, contrasting with a 3.6% loss over the previous four weeks [1][2] Recent Developments - The surge in Hims & Hers Health's shares is linked to the announcement of a deal to sell Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform, allowing U.S. customers to access NovoCare Pharmacy through Hims & Hers for $599 per month [2] Financial Performance Expectations - The company is projected to report quarterly earnings of $0.14 per share, reflecting a year-over-year increase of 180%, with revenues expected to reach $537.85 million, a 93.4% rise from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has been revised 21.3% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - Hims & Hers Health is categorized within the Zacks Medical Info Systems industry, where Health Catalyst (HCAT) is another player, having closed 0.3% higher at $4.07 but showing a -10.4% return over the past month [4]

Core Viewpoint - The article discusses the potential for investing in undervalued stocks that are mispriced by the market, particularly focusing on the company HIMS and its stock performance. Group 1: Investment Opportunities - The article suggests that there may be beneficial long positions available in HIMS through stock purchases or call options within the next 72 hours [2]. - It emphasizes the importance of conducting personal research before making investment decisions, highlighting that past performance does not guarantee future results [4]. Group 2: Market Positioning - The article encourages investors to consider joining platforms like Out Fox The Street for insights on positioning in undervalued stocks [1]. - It notes that the opinions expressed are those of the author and may not reflect broader market views, indicating a level of independence in the analysis [4].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...